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Early cytomegalovirus (CMV) re-activation after allogeneic
hematopoetic stem cell transplantation (allo-HCT) for AML
has been correlated with enhanced graft versus leukemia
(GvL) effect, thus implying an immunogenetic cross-talk
between donor-derived cytotoxic response against both CMV
and leukemia. Data on this are conﬂicting and correlation
could not be conﬁrmed for special group populations. In this
study we explore whether CMV re-activation favors the
outcome in a group of 49 AML patients consecutively allo-
transplanted between 2008-2012. Forty-nine patients (29
male, 20 female), aged 14-63 years (median 42) underwent
allo-HCT with myelo-ablative (42/49) or reduced-intensity
conditioning (7/49), receiving graft from an HLA-identical
sibling (25/49), matched volunteer (23/49) or haplo-identical
(1) donor. Most patients were transplanted in complete
remission (CR), 22/49 in CR1 and 11/49 in CR2 and 16/49
patients had refractory disease. Monitoring of CMV viral load
was performed weekly for 3 months with real-time PCR or
more if patients were treated for GvHD. Upon clinical suspi-
cion, other samples were tested. Overall, 19/49 patients (39%)
presented with CMV reactivation {viremia (>¼1000 copies/
ml) in 16/49, gastritis in 2/49, cystitis in 1) at a median of 46
days post-transplant (13-402). Leukemia relapse occurred in
7/19 patients with CMV at a median of 189 days (2-512),
versus 7/30 CMV-free patients (37% vs 23%, p¼ns). Disease
free survival (DFS) was 591 days for CMV patients (95% CI:
417-939) and 609 for CMV-free (95% CI: 474-871, p¼ns).
Overall survival (OS) was 746 (95% CI:472-963) and 625 (95%
CI:504-899) days, respectively, p¼ns. Only acute and chronic
GvHDwere correlated with longer DFS and OS. Sixteen out of
19 CMV (84%) patients presented with increasing/full donor
chimerism 30 days after reactivation, due to expansion of
donor cytotoxic lymphocytes; however, this did not protect
from imminent relapse. No particular clinical correlations
could be found even for 14/19 patientswith early (<100 days)
CMV reactivation (RR: 28% vs 28% for all other patients, DFS:
714 vs 503 days, OS: 746 vs 625 days, p¼ns for all compari-
sons). In conclusion, CMV reactivation in AML transplanted
patients is not related to graft allo-reactivity. Late relapses in
this cohort of AML patients, transplanted often in remission,
are not inﬂuenced by immunogenetic dynamics at the ﬁrst
semester, when CMV occurs. Regardless CMV re-activation,
OS was comparable in all patients, providing evidence on a
successful pre-emptive treatment of CMV. Larger prospective
studies are strongly warranted in order to explore possible
immunogenetic interactions.380
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Introduction: Bacteremia occurs frequently in the
neutropenic period of earlyallogeneic stemcell transplantation
(SCT). Effective strategies have been developed for
the rapid diagnosis and management of bacteremia inimmunocompromised SCT recipients. We analyzed the inci-
dence of bacteremia during TBI-based myeloablative SCT to
determine the impact on morbidity and mortality in a recent
cohort of patients.
Methods: We studied outcomes in a cohort of 105 consec-
utive ex vivo T cell depleted (TCD) allogeneic transplants
from 6/6 HLA-matched sibling donors between 2006e2014.
Prophylactic antibiotics were not administered. Blood stream
infection (BSI) was deﬁned as the isolation of bacteria from
any blood culture in a four-week window (between days -8
to +21) during the initial hospitalization. All patients had
hematologic malignancies and received myeloablative
conditioning with ﬂudarabine (125 mg/m2), age-adapted
fractionated TBI and cyclophosphamide (120 mg/kg). Frac-
tionated TBI was delivered at a total dose of 1200cGy (with
lung shielding to 600cGy for subjects age <55 years) or 400-
600cGy for subjects age 55 years. All subjects were
managed as inpatients with prompt empiric broad spectrum
antibiotics at the ﬁrst onset of a neutropenic fever.
Results: Successful neutrophil recovery occurred in all sub-
jects and the median time to ANC 500/uL was 13 days. Out
of 105 subjects, 71 (67.5%) had a BSI and 63% occurred be-
tween days 0 to +7. Bacterial species isolated from the blood
were classiﬁed according to their probable site of origin as
oral/cutaneous gram-positive organisms (32%), other sites
(mostly gram-negative) (34%), or mixed (34%). Organisms
classiﬁed as oral/cutaneous were most frequently Strepto-
coccus (44%) or Staphylococcus (43%) species while E. coli
(36%), Klebsiella (27%) and Enterococci (18%) were the most
common isolates classiﬁed as from other sites. One patient
(<1%) succumbed to neutropenic polymicrobial septic shock
on day+7. The occurrence of BSI was not predicted by pre-
transplant factors such as age, gender, type of underlying
malignancy or TBI dose. Even in the subgroup with oral/
cutaneous organisms, BSI was unrelated to the intensity of
oral mucositis (p¼0.16). There was no association between
BSI and early outcomes such as the duration of initial hos-
pitalization (p¼0.70), requirement for total parenteral
nutrition (TPN) (p¼0.38), duration of TPN(p¼0.49) or transfer
to the intensive care unit (p¼0.34). In addition, BSI exerted no
statistically signiﬁcant impact on delayed outcomes such as
non-relapse mortality (p¼0.6) or overall survival (p¼0.5).
Conclusion: Early BSI is common during TBI-based condi-
tioning, with a peak incidence between days 0 and 7, and is
not associatedwith conditioning intensity or presence of oral
mucositis. With optimal management, BSI does not impact
short or long-term outcomes in allogeneic SCT recipients.381
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Allogeneic hematopoetic cell transplantation (allo-HCT) is
currently the only curative treatment option for non-M3
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factors, pretransplant disease status and factors apart from
leukemia could affect the success of allo-SCT. It is still un-
certain that allo-SCT in CR1 has superior efﬁcacy especially
for those patients who have cytogenetically standard risk.
The optimization of supportive care in last 2 decades
decreased early transplant related mortality substantially. In
this intent-to-treat, single center, retrospective study we
analyzed 40 consecutive AML patients who underwent allo-
SCT between January 2011 and November 2013 at our center
to determine the role of allo-SCT in CR1 or beyond. Patients
were evaluated for overall survival (OS), disease free survival
(DFS), early (30-100 day) and late (101-365 day) transplant
related mortality (TRM). Survival was estimated using the
KaplaneMeier method, and the log-rank test was used to
compare survival curves among variables. Median age was
48 years (19-64 y). Among those patients who had cytoge-
netic data (28 patient, 70%), 12 (30%) were in high-risk
category. Median time from diagnosis to allo-HCT was 6.5
months (2-54 months). Median follow-up period for living
patients was 419 days (105-857). Status at tx: 24 patients
(60%) in CR1, 12 patients (30%) in CR2 and 4 patients (10%)
who received myeloablative (Bu16-CY120) (n¼32, 80%) or
reduced-intensity regimens (Flu150-Bu8)(n¼8, 20%). Donors
were matched related for 32 patients (80%), unrelated for 7
patients (17.5%) and haploidentical for 1 patient (2.5%). All
but 2 patients (95%) received PBSC. All patients received
primary antifungal prophylaxis. Overall, TRM at day 30 and
100 were 7.5% (n¼3) and 10% (n¼4), respectively. Late death
(>100 days) was observed in 7 patients (17.5%) and 3 of them
were related to allo-SCT. Grade 2-4 aGVHD was seen in 20
(50%) patients and chronic extensive GVHD in 8 patients
(20%). Of those 24 patients who underwent allo-HCT in CR1,
18 patients (75%) were still in remission without any sign of
disease. Nine of 16 patients (56.3%) who underwent allo-SCT
beyond CR1 lost due to relapsed leukemia. Survival analysis
revealed superior OS between patients in CR1 (median 901
days) and beyond CR1 (median 202 days) (log-rank, OS
p¼0.003)(Fig 1). For disease free survival we have seen the
same proﬁle (p¼0.007). In CR1 patients (n¼24) univariate
analysis revealed no impact of standard-risk cytogenetics,
high HCT-CI (2), high WBC at dx (>30k), sex (F to M), ABO
mismatch and double induction for CR achievement. The
only adverse factor for short OS in CR1 was past history of
invasive fungal infection pre allo-SCT (p¼0.038, 901d vs
553d). Allogeneic HCT in AML patients should be undertakenin CR1 with matched sibling donor. Pre-tx invasive fungal
infection was the only worst predictive factor for OS in CR1.382
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In the Germanmulticentre ALL studies, all patients (pts) with
induction failure or after relapse are candidates for allogeneic
SCT. We report here our single center data on 57 pts. Median
age was 28 years (18-57). ALL subtypes were: Ph+ ALL (n¼8),
B-lineage (pre B, B, pro B) (n¼36), T lineage (pre T, mature T,
thymic) (n¼13). Before conditioning, 12/57 pts had induction
failure, 31/57 pts were in CR2, 8/57 pts in 2. relapse, and 6/57
pts in CR3.Median duration of CR1 (n¼45)was 21months (2-
107), CR2 (n¼14) was 4 months (1-168). Pts with induction
failurehadat leastGMALL, Induction I+II followedby2 further
protocols. Induction chemotherapy of relapse varied and
consisted of the GMALL protocol, ALL relapse protocol, Ida-
FLAG, CLAEG, GIMEMA protocol, and local therapy of extra-
medullary leukemia. 27/37 pts transplanted in CR2 or CR3
reached CR after 1. chemotherapy, 7 after 2. chemotherapy,
and 3 after 3. chemotherapy. Conditioning regimen was
myeloablative (12Gy TBI + Cy/ VP16) in 49 pts, reduced in-
tensity conditioning (8Gy TBI or Flu+Bu+ATG) in 7 pts, and
Treosulfan in 1 pt. Donors were matched unrelated donors
(MUD) in 35 pts, HLA identical siblings in 21 pts, and a HLA-
compatible child in 1 pt. GvHD prophylaxis was mainly CSA/
MTX, since 2005 ATG was given in MUD additionally.
Results: 13/57 pts (23%) are alive in continuous CR (CCR).
The median follow-up after allo-SCT for surviving pts is
155 months (5-222). 26/57 pts died due to relapse, 18/57
pts due to treatment-related mortality (TRM), mainly
GvHD and/or infections. Probability of leukemia free sur-
vival (LFS) at 48 months is 25% for pts with induction
failure, 30% for pts in CR2, 12% for pts in second relapse,
and 33% for pts in CR3.
Conclusions: Adult ALL pts after 1. relapse can only be cured
by allo-SCT, but the relapse rate is high. The same is true for
ALL pts with induction failure/primary refractory. Perspec-
tive in the GMALL studies is to transplant pts with molecular
failure before hematologic relapse occurs. In patients with
induction failure, up to now, allo-SCT is the only chance of
cure. In B-lineage ALL, Blinatumomab may improve the re-
sults as bridging to allo-SCT.383
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